Celerion and the Korean Drug Development Fund announced a formal collaboration
Celerion and the Korean Drug Development Fund (KDDF) announced a formal collaboration to provide drug development expertise and support for the emerging drug discovery and development industry in South Korea. The agreement—in the form of a Memorandum of Understanding (MOU)—provides the framework for collaborations of mutual benefit to both organizations. Companies funded by KDDF will have access to Celerion’s experience and expertise in early clinical research and bioanalysis, as well as the global footprint of external partner sites. The collaboration will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.